Integra LifeSciences (NASDAQ:IART) Stock Bumped Up to Hold by Truist Financial

Key Points

• Truist Financial upgraded Integra LifeSciences to “Hold.” The broader analyst consensus remains “Reduce,” with one Buy, five Hold, and two Sell ratings and an average price target of $18.86.
• Integra reported quarterly EPS of $0.56, exceeding the $0.48 consensus estimate, while revenue of $418.76 million was slightly above forecasts.
• Shares opened at $16.09, compared with a 12-month range of $8.70 to $20.49. Institutional investors own 84.78% of the company, with several major holders recently increasing their stakes.

Integra LifeSciences (NASDAQ:IART - Get Free Report) was upgraded by investment analysts at Truist Financial to a "hold" rating in a note issued to investors on Thursday, Zacks reports.

Other research analysts have also issued research reports about the company. BMO Capital Markets started coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They set a "market perform" rating and a $19.00 price target on the stock. UBS Group assumed coverage on Integra LifeSciences in a report on Tuesday, July 28th. They issued a "neutral" rating and a $19.00 price objective for the company. Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $15.00 to $18.00 and gave the company an "equal weight" rating in a research note on Thursday, July 30th. Citigroup restated a "neutral" rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Finally, Wall Street Zen lowered shares of Integra LifeSciences from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 18th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus target price of $18.86.

Integra LifeSciences Stock Performance

Shares of IART opened at $16.09 on Thursday. The firm has a market cap of $1.25 billion, a P/E ratio of -178.76, a PEG ratio of 0.84 and a beta of 1.21. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $20.49. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The firm's 50 day moving average price is $16.83 and its two-hundred day moving average price is $15.17.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.08. The business had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, analysts forecast that Integra LifeSciences will post 2.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in IART. Paradigm Capital Management Inc. NY raised its position in Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company's stock valued at $37,800,000 after purchasing an additional 1,347,700 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company's stock valued at $26,241,000 after acquiring an additional 160,814 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Integra LifeSciences by 71.4% in the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company's stock worth $13,325,000 after acquiring an additional 589,408 shares during the last quarter. Invenomic Capital Management LP lifted its stake in Integra LifeSciences by 78.3% during the 4th quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company's stock valued at $13,115,000 after acquiring an additional 463,729 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its position in shares of Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company's stock worth $9,276,000 after buying an additional 211,774 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company's products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.